Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 15/20 | 0.82 |
| ▸ | VEGFA | P15692 | 11/20 | 0.82 |
| ▸ | CNR1 | P21554 | 3/20 | 0.39 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL273303 | 0.90 | EGLN1 (1.00) | EGLN1VEGFACNR1CNR2KDM4E | |
| SCHEMBL30274325 | 0.80 | EGLN1 (0.69) | EGLN1VEGFACNR1CNR2KDM4E | |
| SCHEMBL278141 | 0.80 | EGLN1 (0.79) | EGLN1VEGFACNR1CNR2KDM4E | |
| SCHEMBL19478702 | 0.79 | EGLN1 (0.68) | EGLN1VEGFACNR1CNR2KDM4E | |
| SCHEMBL27636343 | 0.77 | EGLN1 (0.65) | EGLN1VEGFACNR1CNR2KDM4E | |
| SCHEMBL272935 | 0.76 | EGLN1 (1.00) | EGLN1VEGFACNR1CNR2KDM4E | |
| SCHEMBL271477 | 0.74 | VEGFA (0.76) | EGLN1VEGFA | |
| SCHEMBL19478697 | 0.73 | EGLN1 (0.78) | EGLN1VEGFAKDM4ETP53CYP2D6 | |
| SCHEMBL16789163 | 0.73 | EGLN1 (0.78) | EGLN1VEGFACNR1CNR2KDM4E | |
| SCHEMBL272882 | 0.72 | VEGFA (0.70) | EGLN1VEGFA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9278930-B2 | Methods for increasing the stabilization of hypoxia inducible factor-α | AERPIO THERAPEUTICS, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150157617-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2015-06-11 | — | — | US | disclosed |
| US-9045495-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-8999971-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2015-04-07 | — | — | US | disclosed |
| US-20140364419-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2014-12-11 | — | — | US | disclosed |
| US-8883774-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8778412-B2 | Methods for increasing the stabilization of hypoxia inducible factor-1 alpha | AERPIO THERAPEUTICS INC. (US) | 2014-07-15 | — | — | US | disclosed |
| US-8536181-B2 | Prolyl hydroxylase inhibitors | AERPIO THERAPEUTICS INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-20130158010-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158045-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | AERPIO THERAPEUTICS LLC | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150157617-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | EGLN1 8/4885VEGFA 20/4885CNR1 3038/4885 |
| US-20130158045-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885VEGFA 551/4885CNR1 1896/4885 |
| US-20110111058-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | EGLN1 8/4885VEGFA 20/4885CNR1 3038/4885 |
| US-20140364419-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | EGLN1 8/4885VEGFA 20/4885CNR1 3038/4885 |
| US-20130158010-A1 | METHODS FOR INCREASING THE STABILIZATION OF HYPOXIA INDUCIBLE FACTOR-1 ALPHA | HIF1A, HIF1AN, EGLN3 | EGLN1 8/4885VEGFA 20/4885CNR1 3038/4885 |
| US-20110110961-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, HIF1A, EGLN2 | EGLN1 5/4885VEGFA 551/4885CNR1 1896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.